Bagsværd, Denmark, 9 February 2017 - Novo Nordisk A/S has filed its Annual Report 2016 on Form 20-F for the financial year 2016 with the US Securities and Exchange Commission (SEC), incorporating by reference parts of the Novo Nordisk A/S Annual Report 2016. The reports are available at the SEC's website, www.sec.gov (http://www.sec.gov/index.htm), as well as on novonordisk.com (http://www.novonordisk.com/annualreport).
Shareholders and ADR holders may receive a hard copy of the annual reports free of charge upon request by filling out a request form on novonordisk.com (http://www.novonordisk.com/annualreport) or upon request to chqt@novonordisk.com (mailto:chqt@novonordisk.com) - please state the exact mailing address and the document(s) you wish to receive.
Further information
Media: | ||
Anne Margrethe Hauge | +45 4442 3450 | amhg@novonordisk.com (mailto:amhg@novonordisk.com) |
Ken Inchausti (US) | +1 609 514 8316 | kiau@novonordisk.com (mailto:kiau@novonordisk.com) |
Investors: | ||
Peter Hugreffe Ankersen | +45 3075 9085 | phak@novonordisk.com (mailto:phak@novonordisk.com) |
Melanie Raouzeos | +45 3075 3479 | mrz@novonordisk.com (mailto:mrz@novonordisk.com) |
Hanna Ögren | +45 3079 8519 | haoe@novonordisk.com (mailto:haoe@novonordisk.com) |
Anders Mikkelsen | +45 3079 4461 | armk@novonordisk.com (mailto:armk@novonordisk.com) |
Kasper Veje (US) | +1 609 235 8567 | kpvj@novonordisk.com (mailto:kpvj@novonordisk.com) |
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire